PYRIMIDINDERIVATE, ARZNEIMITTEL ENTHALTEND DIESE VERBINDUNGEN, DEREN VERWENDUNG UND VERFAHREN ZU IHRER HERSTELLUNG
5-Substituted 2,4-diamino-pyrimidine derivatives (I) are new. Pyrimidines of formula (I) (including tautomers, racemates, enantiomers, diastereomers and their mixtures) and their acid addition salts are new. [Image] R aH or T; T : 1-4C alkyl; R b-T-Ar (optionally substituted (os)) or substituted phe...
Saved in:
Main Authors | , , , , , , , , , , , |
---|---|
Format | Patent |
Language | German |
Published |
15.09.2008
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | 5-Substituted 2,4-diamino-pyrimidine derivatives (I) are new. Pyrimidines of formula (I) (including tautomers, racemates, enantiomers, diastereomers and their mixtures) and their acid addition salts are new. [Image] R aH or T; T : 1-4C alkyl; R b-T-Ar (optionally substituted (os)) or substituted phenyl; R a + R 1 (in the o-position to the N substituted by R a) : 2-4C n-alkylene (os by 1 or 2 T); R 5H, T (os by halo), Ar or -T-Ar; m, n : 1 - 3; or m : 0; and n : 2 - 4; NR cR doptionally substituted alkylene imino group, substituted 3-thiazolidino, optionally substituted pyrrolidino, optionally substituted piperidino, optionally substituted homopiperidino, azetidino (os by T) or an optionally substituted heterobicyclic group; or R cH, 1-8C alkyl, optionally substituted cycloalkyl, optionally substituted -T-(3-7C) cycloalkyl, optionally substituted -T-Ar, 3-5C alkenyl (os by Ar) or 3-5C alkynyl (os by Ar); and R dsubstituted 1-16C alkyl, substituted 4-7C cycloalkyl, dihaloaryl-(1-6C) alkyl (ring-substituted by OH or NH 2), 2- or 3-quinuclidinyl or -T-(2, 3 or 4)-quinuclidinyl; or R cH or T; and R dOH or OT; R ehalo, CN, NO 2, T, OT, NHT, NT 2, COT, ST, SOT, SO 2T, -T-OY, -T-N(T)COT, -T-NHCOT, -T-NHSO 2T, CONH 2, CONHT, CONT 2, -T-NH 2, -T-NHT or -T-NT 2; Me, OMe or SMe substituted by 1-3 F; T', OT' or ST' substituted by 1-5 F; (3-6C) cycloalkyl-(1-3) alkyl (os by 1-6 F); 2-5C alkenyl, 3-5C alkenyloxy, 2-6C alkynyl or 3-6C alkynyloxy (provided unsaturated carbons are not bonded to O); or 4-7 membered alkylene imino group or -T-(4-7 membered alkylene imino group) (os by 1-4 T), where in 6-7 membered AIM the CH 2 in the 4-position is optionally replaced by O, S, SO, SO 2, NH, NT, N-COT, N-SO 2T, NAr or N-T-Ar; T' : 2-4C alkyl; Ar : phenyl (optionally having 1 or 2 C replaced by N and os by up to 5 substituents); Provided that C-atoms of alkyl, alkylene or cycloalkylene moieties bonded to O, S or N are not bonded to a further halo, O, N or S (unless specifically stated otherwise). An independent claim is included for the preparation of (I). ACTIVITY : Virucide; Anti-HIV; Antibacterial; Fungicide; Antiparasitic; Dermatological; Antipsoriatic; Osteopathic; Cardiant; Vasotropic; Cytostatic; Immunosuppressive; Antiinflammatory; Antiarthritic; Neuroprotective; Nootropic; Nephrotropic; Vulnerary. MECHANISM OF ACTION : Protein-Kinase-Inhibitor; SRC-Kinase-Inhibitor; PLK-Kinase-Inhibitor; Aurora-Inhibitor-A; Cyclin-Dependent-Kinase-Inhibitor. 2-(2-Naphthylamino)-4-(3-(2-oxo-pyrrolidin-1-yl)-propylamino)-5-trifluoromethyl-pyrimidine (Ia) had an IC 5 0 value of below 100 nM for inhibition of CDK1/cyclin B1. |
---|---|
Bibliography: | Application Number: AT20020774710T |